KR20170052684A - 치매에서의 초조함을 치료하기 위한 덱스트로메토르판 화합물 및 퀴니딘을 포함하는 약제학적 조성물 - Google Patents

치매에서의 초조함을 치료하기 위한 덱스트로메토르판 화합물 및 퀴니딘을 포함하는 약제학적 조성물 Download PDF

Info

Publication number
KR20170052684A
KR20170052684A KR1020177009991A KR20177009991A KR20170052684A KR 20170052684 A KR20170052684 A KR 20170052684A KR 1020177009991 A KR1020177009991 A KR 1020177009991A KR 20177009991 A KR20177009991 A KR 20177009991A KR 20170052684 A KR20170052684 A KR 20170052684A
Authority
KR
South Korea
Prior art keywords
quinidine
dextromethorphan
administered
salts
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177009991A
Other languages
English (en)
Korean (ko)
Inventor
주앙 시페르트
Original Assignee
아바니르 파마슈티컬스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아바니르 파마슈티컬스, 인코포레이티드 filed Critical 아바니르 파마슈티컬스, 인코포레이티드
Publication of KR20170052684A publication Critical patent/KR20170052684A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020177009991A 2014-09-14 2015-09-14 치매에서의 초조함을 치료하기 위한 덱스트로메토르판 화합물 및 퀴니딘을 포함하는 약제학적 조성물 Ceased KR20170052684A (ko)

Applications Claiming Priority (35)

Application Number Priority Date Filing Date Title
US201462050170P 2014-09-14 2014-09-14
US62/050,170 2014-09-14
US201462061451P 2014-10-08 2014-10-08
US62/061,451 2014-10-08
US201462063122P 2014-10-13 2014-10-13
US62/063,122 2014-10-13
US201462063861P 2014-10-14 2014-10-14
US62/063,861 2014-10-14
US201462068742P 2014-10-26 2014-10-26
US62/068,742 2014-10-26
US201562111053P 2015-02-02 2015-02-02
US62/111,053 2015-02-02
US201562111590P 2015-02-03 2015-02-03
US62/111,590 2015-02-03
US201562128446P 2015-03-04 2015-03-04
US62/128,446 2015-03-04
US201562162140P 2015-05-15 2015-05-15
US62/162,140 2015-05-15
US201562165535P 2015-05-22 2015-05-22
US62/165,535 2015-05-22
US201562169997P 2015-06-02 2015-06-02
US62/169,997 2015-06-02
US201562180026P 2015-06-15 2015-06-15
US62/180,026 2015-06-15
US201562193347P 2015-07-16 2015-07-16
US62/193,347 2015-07-16
US201562205061P 2015-08-14 2015-08-14
US62/205,061 2015-08-14
US201562216636P 2015-09-10 2015-09-10
US62/216,636 2015-09-10
US201562217470P 2015-09-11 2015-09-11
US201562217142P 2015-09-11 2015-09-11
US62/217,142 2015-09-11
US62/217,470 2015-09-11
PCT/US2015/049934 WO2016040930A1 (en) 2014-09-14 2015-09-14 Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia

Publications (1)

Publication Number Publication Date
KR20170052684A true KR20170052684A (ko) 2017-05-12

Family

ID=55459653

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177009991A Ceased KR20170052684A (ko) 2014-09-14 2015-09-14 치매에서의 초조함을 치료하기 위한 덱스트로메토르판 화합물 및 퀴니딘을 포함하는 약제학적 조성물

Country Status (15)

Country Link
US (3) US20190111047A1 (OSRAM)
EP (4) EP4166141A1 (OSRAM)
JP (4) JP2017531033A (OSRAM)
KR (1) KR20170052684A (OSRAM)
CN (3) CN117427077A (OSRAM)
AU (3) AU2015314710A1 (OSRAM)
CA (1) CA2960031A1 (OSRAM)
IL (2) IL250786A0 (OSRAM)
MX (3) MX2017003066A (OSRAM)
MY (1) MY198587A (OSRAM)
PH (1) PH12017500444A1 (OSRAM)
RU (1) RU2017112747A (OSRAM)
SG (2) SG10201901242PA (OSRAM)
TW (3) TW201613591A (OSRAM)
WO (1) WO2016040930A1 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250120917A (ko) 2024-02-02 2025-08-11 단국대학교 천안캠퍼스 산학협력단 덱스트로메토르판을 유효성분으로 포함하는 신경 질환 예방 또는 치료용 약학 조성물
KR20250129211A (ko) 2024-02-22 2025-08-29 단국대학교 천안캠퍼스 산학협력단 데가렐릭스를 유효성분으로 포함하는 신경 질환 예방 또는 치료용 약학적 조성물

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3093290B1 (en) 2007-05-01 2018-01-24 Concert Pharmaceuticals Inc. Morphinan compounds
US20180243289A1 (en) * 2015-07-30 2018-08-30 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for treating agitation
US20180243291A1 (en) * 2015-07-30 2018-08-30 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for treating agitation
ES2925277T3 (es) * 2016-07-04 2022-10-14 Avanir Pharmaceuticals Inc Métodos para la síntesis de dextrometorfano deuterado
KR20200062078A (ko) * 2017-05-04 2020-06-03 익스시바 게엠베하 신규 조성물, 조합 및 그의 방법을 갖는 표적 약물 구제
US11478467B2 (en) 2017-05-04 2022-10-25 Sreenivasarao Vepachedu Targeted drug rescue with novel compositions, combinations, and methods thereof
JP7582869B2 (ja) 2018-05-18 2024-11-13 アナベックス ライフ サイエンス コーポレイション レスポンダ選択および治療の最適化されたｓｉｇｍａ－１アゴニスト方法
CN114712357A (zh) * 2019-01-07 2022-07-08 安泰赛普生物风投二代有限责任公司 用于治疗抑郁症的右美沙芬和安非他酮的组合
EP3941469A4 (en) * 2019-03-18 2022-05-18 Avanir Pharmaceuticals, Inc. METHODS OF TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA USING DEUTTERATED DEXTROMETHORPHANE AND QUINIDINE
CA3176234A1 (en) * 2020-04-27 2021-11-04 Sanjay Dube Methods of treating agitation associated with alzheimer's disease
WO2022228363A1 (zh) * 2021-04-27 2022-11-03 杭州剂泰医药科技有限责任公司 一种组合物的医药用途
CN115322150B (zh) * 2021-05-11 2024-05-28 深圳信立泰药业股份有限公司 氘代右美沙芬氢溴酸盐的固体及其制备方法和医药用途
CN113209042A (zh) * 2021-05-28 2021-08-06 珠海润都制药股份有限公司 一种氢溴酸右美沙芬硫酸奎尼丁胶囊及其制备方法
WO2023076414A1 (en) * 2021-10-27 2023-05-04 Avanir Pharmaceuticals, Inc. Methods of treating agitation associated with alzheimer's disease
CN116459255A (zh) * 2022-01-19 2023-07-21 深圳信立泰药业股份有限公司 氘代右美沙芬与安非他酮联合在制备ad激越的药物中的用途
US11730706B1 (en) * 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5166207A (en) 1991-06-17 1992-11-24 Neurotherapeutics, Inc. Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders
US5350756A (en) 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
US5366980A (en) 1991-06-17 1994-11-22 Smith Richard A Use of dextromethorphan and an oxidase inhibitor to treat dermatitis
US5206248A (en) 1992-03-27 1993-04-27 Smith Richard A Method for reducing emotional lability
TW264473B (OSRAM) * 1993-01-06 1995-12-01 Hoffmann La Roche
USRE38115E1 (en) 1994-09-22 2003-05-06 Center For Neurologic Study Dextromethorphan and an oxidase inhibitor for treating intractable conditions
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
US5922683A (en) 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
ES2352739T3 (es) 1997-11-21 2011-02-22 Purdue Neuroscience Company 2-aminoacetamidas sustituidas y el uso de las mismas.
IL137974A0 (en) 1998-03-26 2001-10-31 Shionogi & Co Indole derivatives having antiviral activity
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
FR2784988B1 (fr) 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TWI326214B (en) * 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
KR20080097443A (ko) * 2006-02-03 2008-11-05 아바니르 파마슈티컬스 덱스트로메토판 및 퀴니딘을 포함하는, 우울, 불안 및 신경퇴행성 장애 치료용 약제학적 조성물
EP2001534A4 (en) * 2006-03-07 2013-07-03 Univ Florida SYSTEM FOR MONITORING THE COMPLIANCE OF MEDICINAL DOSES
WO2008097924A2 (en) * 2007-02-05 2008-08-14 Avanir Pharmaceuticals Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
EP3093290B1 (en) * 2007-05-01 2018-01-24 Concert Pharmaceuticals Inc. Morphinan compounds
ES2401892T3 (es) * 2007-05-01 2013-04-25 Concert Pharmaceuticals Inc. Compuestos morfinanos
ES2750825T3 (es) * 2008-09-19 2020-03-27 Concert Pharmaceuticals Inc Compuestos de morfinano deuterados
HUE028956T2 (en) * 2008-10-30 2017-01-30 Concert Pharmaceuticals Inc Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect
MX2011005112A (es) * 2008-11-14 2011-06-16 Concert Pharmaceuticals Inc Derivados de dioxopiperidinil-ftalimida sustituida.
JP6605485B2 (ja) * 2013-11-05 2019-11-13 アンテシップ バイオベンチャーズ トゥー エルエルシー ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250120917A (ko) 2024-02-02 2025-08-11 단국대학교 천안캠퍼스 산학협력단 덱스트로메토르판을 유효성분으로 포함하는 신경 질환 예방 또는 치료용 약학 조성물
KR20250129211A (ko) 2024-02-22 2025-08-29 단국대학교 천안캠퍼스 산학협력단 데가렐릭스를 유효성분으로 포함하는 신경 질환 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
IL250786A0 (en) 2017-04-30
EP4166141A1 (en) 2023-04-19
RU2017112747A (ru) 2018-10-15
AU2020289733A1 (en) 2021-01-21
CN107072990A (zh) 2017-08-18
EP3932907A2 (en) 2022-01-05
MY198587A (en) 2023-09-06
TWI869633B (zh) 2025-01-11
RU2020116666A (ru) 2020-07-31
MX2022008181A (es) 2022-08-10
EP3708168A3 (en) 2020-12-09
MX2021010696A (es) 2021-10-01
TW202231278A (zh) 2022-08-16
AU2022283671B2 (en) 2025-03-20
PH12017500444A1 (en) 2017-07-31
RU2017112747A3 (OSRAM) 2019-04-29
WO2016040930A1 (en) 2016-03-17
EP3708168A2 (en) 2020-09-16
US20200289499A1 (en) 2020-09-17
AU2015314710A1 (en) 2017-04-20
SG11201701645WA (en) 2017-04-27
US20190111047A1 (en) 2019-04-18
CN117427077A (zh) 2024-01-23
IL274742A (en) 2020-07-30
MX2017003066A (es) 2017-09-12
SG10201901242PA (en) 2019-03-28
AU2022283671A1 (en) 2023-02-02
EP3193872A4 (en) 2018-02-28
JP2017531033A (ja) 2017-10-19
CA2960031A1 (en) 2016-03-17
JP2023105265A (ja) 2023-07-28
TW202106301A (zh) 2021-02-16
CN110664801A (zh) 2020-01-10
US20240082237A1 (en) 2024-03-14
JP2020019818A (ja) 2020-02-06
TW201613591A (en) 2016-04-16
EP3193872A1 (en) 2017-07-26
JP2021080300A (ja) 2021-05-27
JP7360409B2 (ja) 2023-10-12
EP3932907A3 (en) 2022-03-30

Similar Documents

Publication Publication Date Title
AU2022283671B2 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
US20220105084A1 (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of agitation in dementia
Silva et al. Pharmacokinetics and pharmacodynamics of dextromethorphan: clinical and forensic aspects
Dwoskin et al. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent
Pahwa et al. New antipsychotic medications in the last decade
WO2012118562A1 (en) Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
US20090068290A1 (en) Bifeprunox doses for treating schizophrenia
CN110167562A (zh) Dmpc、dmpg、dmpc/dmpg、lysopg和lysopc针对引起离子通道病的药物的保护作用
Bobo Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults
Schweri et al. Biochemical and behavioral characterization of novel methylphenidate analogs
RU2838188C2 (ru) Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции
HK40091857A (en) Combinations of deuterated dextromethorphan and quinidine for the treatment of agitation and aggression in alzheimer's dementia
HK40064052A (en) Dextromethorphan analogs and combinations of deuterated dextromethorphan and nortriptyline for use in treating agitation and/or aggression
HK40020899A (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
HK1235689A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
Pope AVP-923 as a novel treatment for pseudobulbar affect in ALS
Whitebread et al. Side effects of marketed drugs: The utility and pitfalls of pharmacovigilance
White et al. Pipradrol and pipradrol derivatives
Carroll 2006 NATHAN B. EDDY MEMORIAL AWARD LECTURE
WO2004078177A1 (ja) 薬物・物質依存治療薬
Brady Phillip S. Portoghese and Akira E. Takemori
Meyer Jonathan M. Meyer, MD

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination